INBS Fundamental Analysis - INTELLIGENT BIO SOLUTIONS IN

Fundamental Rating

Overall INBS gets a fundamental rating of 3 out of 10. We evaluated INBS against 187 industry peers in the Health Care Equipment & Supplies industry. INBS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. INBS has a decent growth rate and is not valued too expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year INBS has reported negative net income.

In the past year INBS has reported a negative cash flow from operations.

In the past 5 years INBS always reported negative net income.

In the past 5 years INBS always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -107.08%, INBS is doing worse than 82.35% of the companies in the same industry.

INBS has a Return On Equity of -200.70%. This is in the lower half of the industry: INBS underperforms 74.33% of its industry peers.

		Industry Rank	Sector Rank
ROA	-107.08%
ROE	-200.7%
ROIC	N/A

ROA(3y)-81.21%

ROA(5y)-80.72%

ROE(3y)-175.72%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 58.81%, INBS is in line with its industry, outperforming 57.75% of the companies in the same industry.

INBS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	58.81%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

INBS does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, INBS has more shares outstanding

The number of shares outstanding for INBS has been increased compared to 5 years ago.

The debt/assets ratio for INBS has been reduced compared to a year ago.

2.2 Solvency

INBS has an Altman-Z score of -10.16. This is a bad value and indicates that INBS is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -10.16, INBS is not doing good in the industry: 81.82% of the companies in the same industry are doing better.

There is no outstanding debt for INBS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-10.16

ROIC/WACCN/A

WACC8.79%

2.3 Liquidity

INBS has a Current Ratio of 1.12. This is a normal value and indicates that INBS is financially healthy and should not expect problems in meeting its short term obligations.

INBS's Current ratio of 1.12 is on the low side compared to the rest of the industry. INBS is outperformed by 86.10% of its industry peers.

INBS has a Quick Ratio of 1.12. This is a bad value and indicates that INBS is not financially healthy enough and could expect problems in meeting its short term obligations.

INBS's Quick ratio of 0.97 is on the low side compared to the rest of the industry. INBS is outperformed by 77.54% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.12
Quick Ratio	0.97

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

INBS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.01%, which is quite impressive.

INBS shows a small growth in Revenue. In the last year, the Revenue has grown by 3.87%.

Measured over the past years, INBS shows a very strong growth in Revenue. The Revenue has been growing by 589.28% on average per year.

EPS 1Y (TTM)96.01%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%69.18%

Revenue 1Y (TTM)3.87%

Revenue growth 3Y16.26%

Revenue growth 5Y589.28%

Sales Q2Q%-11.54%

3.2 Future

Based on estimates for the next years, INBS will show a very strong growth in Earnings Per Share. The EPS will grow by 44.75% on average per year.

INBS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 150.78% yearly.

EPS Next Y65.94%

EPS Next 2Y44.75%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year177.96%

Revenue Next 2Y150.78%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INBS. In the last year negative earnings were reported.

INBS is valuated cheaply with a Price/Forward Earnings ratio of 5.18.

Compared to the rest of the industry, the Price/Forward Earnings ratio of INBS indicates a rather cheap valuation: INBS is cheaper than 97.33% of the companies listed in the same industry.

Compared to an average S&P500 Price/Forward Earnings ratio of 22.19, INBS is valued rather cheaply.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	5.18

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

INBS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as INBS's earnings are expected to grow with 44.75% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y44.75%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for INBS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

INTELLIGENT BIO SOLUTIONS IN

NASDAQ:INBS (6/18/2025, 8:00:01 PM)

After market: 1.84 -0.01 (-0.54%)

1.85

-0.08 (-4.15%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)11-07 2024-11-07/bmo

Earnings (Next)N/A N/A

Inst Owners12.83%

Inst Owner Change510.86%

Ins Owners0.79%

Ins Owner Change0%

Market Cap12.78M

Analysts85.71

Price Target12.24 (561.62%)

Short Float %7.75%

Short Ratio4.58

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-76.04%

Min Revenue beat(2)-78.54%

Max Revenue beat(2)-73.53%

Revenue beat(4)0

Avg Revenue beat(4)-63.33%

Min Revenue beat(4)-78.54%

Max Revenue beat(4)-50.1%

Revenue beat(8)0

Avg Revenue beat(8)-44.11%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	5.18
P/S	4.35
P/FCF	N/A
P/OCF	N/A
P/B	2.5
P/tB	9.76
EV/EBITDA	N/A

EPS(TTM)-2.56

EYN/A

EPS(NY)0.36

Fwd EY19.3%

FCF(TTM)-1.51

FCFYN/A

OCF(TTM)-1.51

OCFYN/A

SpS0.42

BVpS0.74

TBVpS0.19

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-107.08%
ROE	-200.7%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	58.81%
FCFM	N/A

ROA(3y)-81.21%

ROA(5y)-80.72%

ROE(3y)-175.72%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0.31

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.12
Quick Ratio	0.97
Altman-Z	-10.16

F-Score3

WACC8.79%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)96.01%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%69.18%

EPS Next Y65.94%

EPS Next 2Y44.75%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)3.87%

Revenue growth 3Y16.26%

Revenue growth 5Y589.28%

Sales Q2Q%-11.54%

Revenue Next Year177.96%

Revenue Next 2Y150.78%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-2.4%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-22.32%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-22.25%

OCF growth 3YN/A

OCF growth 5YN/A

INTELLIGENT BIO SOLUTIONS IN (INBS) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens